Abstract: The invention relates to new 4-aryl-2-methyl-1,2,3,4-tetrahydro-isoquinoline derivatives of the general Formula I ##STR1## and salts thereof whereinR stands for hydrogen, lower alkyl or halogen andX represents a group of the general Formula --(CH.sub.2).sub.n --NR.sup.1 R.sup.2, --NH--R.sup.3 or --OR.sup.4, in whichR.sup.1 and R.sup.2 may be the same or different and stand for hydrogen or lower alkyl or R.sup.1 and R.sup.2 together with the adjacent nitrogen atom, they are attached to, form a 5- or 6-membered saturated heterocyclic ring which may optionally contain a further oxygen or sulfur atom or an optionally lower alkyl substituted imino group;n is an integral number 1, 2, 3 or 4;R.sup.3 stands for lower alkyl or optionally substituted phenyl andR.sup.4 is lower alkyl, halogeno lower alkyl, or phenyl lower alkyl.The compounds of the general Formula I are useful as antidepressants and antiparkinsone agents.The compounds of the general Formula I can be prepared by methods known per se.

Abstract: Compounds of the formula ##SPC1##WhereinR.sub.1 and R.sub.2 each represent hydrogen or a straight-chained or branched C.sub.1.sub.-3 alkyl group,R stands for hydrogen or a straight-chained or branched C.sub.1.sub.-4 alkyl group,R.sub.3 stands for hydrogen or a straight-chained or branched C.sub.1.sub.-4 alkyl group.The new compounds of formula (I) possess valuable pharmacological properties, and act, primarily, on the central nervous system. Thus they can be used in the therapy first of all as the active agents of anticonvulsive medicines.